The U.S. Food and Drug Administration will expedite the approval process for Moderna's MPNA-1273 vaccine against the new coronavirus. The company is awaiting a full set of clinical data from the NIAID-led Phase 1 study and is actively preparing for Phase 2 and Phase 3 clinical trials to further explore the potential of MPNA-1273.
The U.S. Food and Drug Administration will expedite the approval process for Moderna's MPNA-1273 vaccine against the new coronavirus. The company is awaiting a full set of clinical data from the NIAID-led Phase 1 study and is actively preparing for Phase 2 and Phase 3 clinical trials to further explore the potential of MPNA-1273. 
investors.modernatx.com
English (US) 